A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with diff Erent anti-tumor necrosis factor therapies: A retrospective observational study

Modern Rheumatology

Volumn 25, Issue 3, 2015, Pages 344-349

  Hirata, Shintaro ^a   Li, Wanying ^b   Defranoux, Nadine ^b   Cavet, Guy ^b,c   Bolce, Rebecca ^b   Yamaoka, Kunihiro ^a   Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Crescendo Bioscience Inc   (United States)

^c Atreca Inc   (United States)

Author keywords

Biomarkers; Disease activity; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ADJUVANT; ANGIOTENSIN RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT; CARVEDILOL; CLOPIDOGREL; DIURETIC AGENT; METOPROLOL; NEBIVOLOL; NITRIC ACID DERIVATIVE; VITAMIN; ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; ETANERCEPT; INFLIXIMAB;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG COST; DRUG INFORMATION; DRUG OVERDOSE; ETHICS; HEALTH PROMOTION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; WORLD HEALTH ORGANIZATION; ADULT; AGED; ARTHRITIS, RHEUMATOID; DISEASE COURSE; FEMALE; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; DISEASE PROGRESSION; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84929472825     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.958893     Document Type: Article

References (25)

1. Smolen JS, Aletaha D, Bijlsma JW Breedveld FC, Boumpas D, Burmester G, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-7.
2. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007;66(Suppl 3):56-60.
3. Singh JA, Fürst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39.
4. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(1):34-45.
5. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8(4):e60635.
6. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20(3):579-81.
7. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66(3):407-9.
8. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745-57.
9. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.
10. Smolen JS, Breedveld FC, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244-57.
11. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen J S. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806.
12. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S100-08.
13. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35(11):2136-47.
14. Grunke M, Antoni CE, Kavanaugh A, Hildebrand V, Dechant C, Schett G, et al. Standardization of joint examination technique leads to a significant decrease in variability among different examiners. J Rheumatol. 2010;37(4):860-4.
15. Klinkhoff A, Bellamy N, Bombardier C, Carette S, Chalmers A, Esdaile JM, et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988; 15(3): 492-4.
16. Mease PJ. The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clin Exp Rheumatol. 2011;29(3):567-74.
17. Curtis JR, van der Helm-van, Mil AH, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, et al. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64(12):1794-803.
18. Bakker MF, Cavet G, Jacobs JW, Bijlsma JW, Haney DJ, Shen Y, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012;71(10):1692-7.
19. Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford, England). 2013; 52(7): 1202-7.
20. Burmester G, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013;72(9):1445-52.
21. van der Helm-van, Mil AHM, Knevel R, Cavet G, Huizinga TWJ, Haney DJ. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford, England). 2013;52(5):839-46.
22. Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, et al. Pre-treatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204986
23. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al.; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84.
24. Japan College of Rheumatology. TNF inhibitor use guidelines for rheumatoid arthritis (RA) (2012 revised edition) (in Japanese). http://www.ryumachi-jp.com/info/guideline_TNF_120704.html. Accessed 3 December 2013.
25. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, Hesterberg LK. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415-24.